Alzamend Neuro Completes Phase II Clinical Trial of AL001 to Transform Lithium Therapy Alzamend Neuro has finalized the clinical segment of its Phase II trial for AL001, aiming to revolutionize lithium treatment for mental health disorders. Topline data expected in early 2026.

Alzamend Neuro Completes Phase II Clinical Trial of AL001 to Transform Lithium Therapy #United_States #Atlanta #Alzamend_Neuro #AL001 #Lithium_Therapy